72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
22 citations
,
April 1998 in “Dermatologic Clinics” Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
2 citations
,
June 2020 in “Clinical Journal of Gastroenterology” Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
6 citations
,
May 2018 in “Zeitschrift für Rheumatologie” A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
56 citations
,
September 2016 in “Pharmaceutical Research” The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
25 citations
,
March 2021 in “Australasian Journal of Dermatology” Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
MTX and GC combinations are the most effective for early rheumatoid arthritis.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
31 citations
,
July 1975 in “PubMed” Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
May 2026 in “Frontiers in Immunology” Bimekizumab effectively treats scalp cellulitis and improves quality of life.